fluoxetine has been researched along with Asthma in 4 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Asthma: A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Depression is very common in asthmatic patients and may increases risk for morbidity and mortality." | 5.48 | Fluoxetine protects against OVA induced bronchial asthma and depression in rats. ( Abo-Youssef, AM; Ismaiel, IE; Salama, AAA; Sherkawy, MM, 2018) |
| "Depression is very common in asthmatic patients and may increases risk for morbidity and mortality." | 1.48 | Fluoxetine protects against OVA induced bronchial asthma and depression in rats. ( Abo-Youssef, AM; Ismaiel, IE; Salama, AAA; Sherkawy, MM, 2018) |
| "In the septic shock model, all three drugs given preventively markedly decreased circulating levels of TNF-alpha and mortality (50% mortality in fluoxetine treated group, 30% in desipramine and prednisolone treated groups versus 90% in controls)." | 1.34 | Anti-inflammatory properties of desipramine and fluoxetine. ( Bichon, F; Detoc, M; Henriquet, C; Jaffuel, D; Mathieu, M; Michel, A; Portet, K; Roumestan, C, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Casan, P | 1 |
| Fernández Tena, A | 1 |
| MartÃnez, C | 1 |
| Sherkawy, MM | 1 |
| Abo-Youssef, AM | 1 |
| Salama, AAA | 1 |
| Ismaiel, IE | 1 |
| Roumestan, C | 1 |
| Michel, A | 1 |
| Bichon, F | 1 |
| Portet, K | 1 |
| Detoc, M | 1 |
| Henriquet, C | 1 |
| Jaffuel, D | 1 |
| Mathieu, M | 1 |
| Zaitsev, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Fluoxetine to Reduce Hospitalization From COVID-19 Infection (FloR COVID-19)[NCT04570449] | Early Phase 1 | 0 participants (Actual) | Interventional | 2020-11-30 | Withdrawn (stopped due to Study timeline is not feasible) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 other studies available for fluoxetine and Asthma
| Article | Year |
|---|---|
More Platon And Less Prozac: The Arrival Of ASTHMA-ZUMAB.
Topics: Adrenal Cortex Hormones; Anti-Asthmatic Agents; Antibodies, Monoclonal; Asthma; Attitude of Health P | 2018 |
Fluoxetine protects against OVA induced bronchial asthma and depression in rats.
Topics: Animals; Asthma; Brain-Derived Neurotrophic Factor; Depression; Dexamethasone; Fluoxetine; Immunoglo | 2018 |
Anti-inflammatory properties of desipramine and fluoxetine.
Topics: Animals; Anti-Inflammatory Agents; Antidepressive Agents; Asthma; Cells, Cultured; Cytokines; Desipr | 2007 |
[Dyspnoea of a young male patient].
Topics: Adult; Antidepressive Agents, Second-Generation; Asthma; Diagnosis, Differential; Dyspnea; Fluoxetin | 1996 |